StockFetcher Forums · General Discussion · Detective Work V<< >>Post Follow-up
TheRumpledOne
6,358 posts
msg #40610
Ignore TheRumpledOne
1/23/2006 7:32:15 AM

In today's email:

"[The company] had a very successful year in 2005," according to the update by SISM Research and Investment Services. "The Company entered (a) decisively strategic expansion stage, more than doubled its portfolio of Intellectual Property, successfully completed animal testing proceeding clinical evaluation of its proprietary hydroxyapatite coating technology for cardiovascular stents and other implantable medical devices and progressed to the next stage with preliminary evaluation of its novel Aortic Embolic Protection Device."

Report author Ernest C. Schlotter, Senior Analyst with Zurich, Switzerland-based SISM, also reiterates the Company's innovative leadership in the burgeoning field of advanced, safe and biocompatible stent technologies and concludes with a strong endorsement of the Company's projected growth potential.

In the new update to the fee-based research coverage, Mr. Schlotter also includes the following highlights expected in 2006 and beyond:

Completion of necessary preclinical/animal studies for its proprietary "SMART" drug delivery technologies, to provide customized, optimized therapeutic benefits to patients requiring controlled, gradual release of drugs from their implanted devices.
Commencement of human clinical trials of its first commercial product, a drug eluting "Smart-1" system combined with ultra-thin HAp stent coating formulation, which is designed primarily to protect surrounding tissue from chemical interaction with bare-metal stents. If human clinical trials are successful, the Company could get CE clearance for marketing of its product in 2007 and FDA approval approximately fifteen to eighteen months later.
Commencement of human clinical trials of its HAp-based drug-eluting stent using a thicker and nanoporous coating suitable for polymer-free drug delivery purposes. This thicker coating will be loaded with a suitable drug, that is anti-inflammatory and anti-restenotic. Drug-eluting stents have broad applications in both cardiovascular and non-cardiovascular drug/device combination products such as peripheral stents, biodegradable implants, gene therapy, and delivery systems for the release of chemotherapeutic agents. CE approval is expected in 2008.

The company featured in the above Stockgroup Media Inc. NewsBlast has paid a fee in cash or stock to have their corporate information featured. The information shown is purely and solely the responsibility of the company featured, it is not the responsibility of Stockgroup Media Inc, whose only function is as a supplier of media facilities. Any information provided by the advertisers of Stockgroup Media Inc., through its media services, is not to be construed as a recommendation or suggestion or offer to buy or sell securities. All due diligence should be done by the reader when investing in securities.
Your information is shared only with the company featured in this NewsBlast and will not be sold or rented to any other third party. The company featured may contact you from time to time with updates.
NewsBlasts are sent on a request-only basis. If you wish to unsubscribe from (), please use this link to cancel future deliveries. For more information on how to get your company featured, please contact us at sales@stockhouse.com. Thank you. Copyright Stockgroup Media Inc. All Rights Reserved.

=============================================================================
So I goggled " proprietary "SMART" drug delivery technologies"

and got this (only 1 hit!):

MIV Therapeutics' 6-Month Price Target of $2.50 Reaffirmed in Newly Updated SISM Research Report; Biocompatible Stent Coating Developer's Progress Reflected in Robust Target Price Re-Statement and Speculative Buy Rating


VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan 11, 2006 - MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems, announced today that a leading industry researcher has reaffirmed a 6-month target price projection of $2.50 in a newly updated paid research report that reflects the Company's 2005 technology achievements.

"MIVT had a very successful year in 2005," according to the update by SISM Research and Investment Services. "The Company entered (a) decisively strategic expansion stage, more than doubled its portfolio of Intellectual Property, successfully completed animal testing proceeding clinical evaluation of its proprietary hydroxyapatite coating technology for cardiovascular stents and other implantable medical devices and progressed to the next stage with preliminary evaluation of its novel Aortic Embolic Protection Device."



Report author Ernest C. Schlotter, Senior Analyst with Zurich, Switzerland-based SISM, also reiterates the Company's innovative leadership in the burgeoning field of advanced, safe and biocompatible stent technologies and concludes with a strong endorsement of the Company's projected growth potential.

In the new update to the fee-based research coverage, Mr. Schlotter also includes the following MIVT highlights expected in 2006 and beyond:

-- Completion of necessary preclinical/animal studies for its proprietary "SMART" drug delivery technologies, to provide customized, optimized therapeutic benefits to patients requiring controlled, gradual release of drugs from their implanted devices.

-- Commencement of human clinical trials of its first commercial product, a drug eluting "Smart-1" system combined with ultra-thin HAp stent coating formulation, which is designed primarily to protect surrounding tissue from chemical interaction with bare-metal stents. If human clinical trials are successful, the Company could get CE clearance for marketing of its product in 2007 and FDA approval approximately fifteen to eighteen months later.

-- Commencement of human clinical trials of its HAp-based drug-eluting stent using a thicker and nanoporous coating suitable for polymer-free drug delivery purposes. This thicker coating will be loaded with a suitable drug, that is anti-inflammatory and anti-restenotic. Drug-eluting stents have broad applications in both cardiovascular and non-cardiovascular drug/device combination products such as peripheral stents, biodegradable implants, gene therapy, and delivery systems for the release of chemotherapeutic agents. CE approval is expected in 2008.

In addition, the SISM update also emphasizes the Company's "world class Management Team, which will be able to successfully execute the Company's aggressive business strategy and bring its products to the marketplace." MIVT is very close to the commencement of human clinical trials and is nearing with every day to the commercialization of its products, the update continues.

"This will help the Company to realize the full potential of its earning power and drive its valuation. The present status of quickly maturing technology offers an exceptionally favorable risk/reward for risk-tolerant, capital gains oriented investors who can see the long-term growth potential of this unique and innovative Company. We have therefore reaffirmed our six-month target price of $2.50 but still maintain our Speculative Buy/4 rating for the stock of MIV Therapeutics."

MIVT's proprietary Hydroxyapatite (HAp) coating technologies are increasingly being recognized as inherently safer, naturally bio-porous alternatives to inferior polymer products on the market. HAp can be found in human bone and teeth and has been used successfully for years in other, unrelated therapeutic applications.

MIVT has a valuable Intellectual Property portfolio of more than 40 proprietary solutions based on its advanced HAp technologies. The full SISM Research update can be found at http://www.trilogy-capital.com/tcp/mivt/sism_report.html.

About SISM Research

SISM Research, based in Zurich, Switzerland, is a private investment research firm offering high-quality, independent, fundamental research on public companies since 1995. SISM writes, publishes and distributes research coverage, in both English and German, on micro- to small-cap public companies trading on the OTC Bulletin Board, NASDAQ and AMEX. This coverage is geared toward institutional and individual investors in both North America and in German-speaking Europe, a market that represents more than 100 million people. SISM Research is a content provider to Thomson Financials OneAnalytics/FirstCall, to Multex, and InvesTrend. Both SISM Research and InvesTrend Research subscribe to the "Standards for Independent Research Providers." MIV Therapeutics will pay SISM Research $1,750 per month over a two-year period solely to ensure independent coverage.

About MIV Therapeutics, Inc.

MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company's drug eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug-eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit: http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is also traded on the Frankfurt Stock Exchange under the ticker symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Contact MIV Therapeutics, Inc. Investor Relations, 604-301-9545 Toll-free: 800-221-5108 Fax: 604-301-9546 E-mail: investor@mivtherapeutics.com Web: www.mivtherapeutics.com or for Product Inquiries and Business Opportunities: Arc Rajtar, 604-301-9545 Ext. 22 arajtar@mivi.ca or Trilogy Capital Partners Paul Karon, Toll-free: 800-342-1467 paul@trilogy-capital.com







StockFetcher Forums · General Discussion · Detective Work V<< >>Post Follow-up

*** Disclaimer *** StockFetcher.com does not endorse or suggest any of the securities which are returned in any of the searches or filters. They are provided purely for informational and research purposes. StockFetcher.com does not recommend particular securities. StockFetcher.com, Vestyl Software, L.L.C. and involved content providers shall not be liable for any errors or delays in the content, or for any actions taken based on the content.


Copyright 2016 - Vestyl Software L.L.C.Terms of Service | License | Questions or comments? Contact Us
EOD Data sources: DDFPlus & CSI Data Quotes delayed during active market hours. Delay times are at least 15 mins for NASDAQ, 20 mins for NYSE and Amex. Delayed intraday data provided by DDFPlus